Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Thomas C. Luke"'
Autor:
Zhuoming Liu, Hua Wu, Kristi A. Egland, Theron C. Gilliland, Matthew D. Dunn, Thomas C. Luke, Eddie J. Sullivan, William B. Klimstra, Christoph L. Bausch, Sean P. J. Whelan
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 2 (2022)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with amino-acid substitutions and deletions in spike protein (S) can reduce the effectiveness of monoclonal antibodies (mAbs) and may compromise immunity induced by vaccines. We re
Externí odkaz:
https://doaj.org/article/e29eb5cbee9140b8aba60e64edfb7434
Autor:
Brian J. Morrison, Nicholas J. Martin, Tauseef Rehman, Dan Ewing, Robin L. Dewar, Julia Metcalf, Peifang Sun, John Beigel, Thomas C. Luke, Kanakatte Raviprakash
Publikováno v:
BMC Health Services Research, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background The hemagglutination-inhibition (HAI) assay is a critical component for measurement of immunogenicity in influenza vaccine development. It is unknown if the results can be influenced by sample type and anticoagulants. The purpose
Externí odkaz:
https://doaj.org/article/6a34611baed8484a89d87b64d78d26bf
Autor:
Juanjie, Tang, Gabrielle, Grubbs, Youri, Lee, Hua, Wu, Thomas C, Luke, Kristi A, Egland, Christoph L, Bausch, Eddie J, Sullivan, Surender, Khurana
Publikováno v:
The Journal of Infectious Diseases. 226:655-663
Passive antibody immunotherapeutics directed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are promising countermeasures for protection and treatment of coronavirus disease 2019 (COVID-19). SARS-CoV-2 variants of concern (VOCs)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ad15458afbbfaa38e77bc89a25f65e4
https://doi.org/10.1093/infdis/jiac031
https://doi.org/10.1093/infdis/jiac031
SAB-185 is a fully human polyclonal anti-SARS-CoV-2 immunoglobulin produced from the plasma of transchromosomic bovines that are hyperimmunized with recombinant SARS-CoV-2 Wuhan-Hu-1 Spike protein. SAB-185 is being evaluated for efficacy in aphase 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62ba267453244bf63e81d9cf89fd8d47
https://doi.org/10.1101/2021.08.09.454215
https://doi.org/10.1101/2021.08.09.454215
Autor:
Yutaka Terada, Maria Alcorn, Kristi A Egland, Theron Gilliland, Deanna Larson, Zhongde Wang, Shauna N. Vasilatos, Jeneveve D. Lundy, Eddie Sullivan, Thomas C. Luke, Rong Li, Christoph L Bausch, Zachary Ryckman, William B. Klimstra, Hua Wu, Emily L. Cottle, Matthew D. Dunn, Yanan Liu
Publikováno v:
bioRxiv
Pandemic SARS CoV-2 has been undergoing rapid evolution during spread throughout the world resulting in the emergence of many Spike protein variants, some of which appear to either evade antibody neutralization, transmit more efficiently, or potentia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::183762c2dce43cd4bc3df746229a45c1
https://doi.org/10.1101/2021.07.26.453840
https://doi.org/10.1101/2021.07.26.453840
Autor:
Eddie Sullivan, Zhuoming Liu, Christoph L Bausch, Kristi A Egland, Theron C. Gilliland, Thomas C. Luke, Sean P. J. Whelan, Hua Wu, Matthew D. Dunn, William B. Klimstra
Publikováno v:
Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with amino-acid substitutions and deletions in spike protein (S) can reduce the effectiveness of monoclonal antibodies (mAbs) and may compromise immunity induced by vaccines. We re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4db95e951499a0deadcdb5fd3ce060a6
https://pubmed.ncbi.nlm.nih.gov/34228597
https://pubmed.ncbi.nlm.nih.gov/34228597
Publikováno v:
Military medicine.
Introduction Staphylococcus aureus (SA) is a major human bacterial pathogen increasingly refractory to antibiotics. Given the dearth of novel antibiotics in the developmental pipeline, we require concerted efforts at optimizing novel antimicrobial ap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41b350b8513a3869aadee9179bf1141a
https://pubmed.ncbi.nlm.nih.gov/34179992
https://pubmed.ncbi.nlm.nih.gov/34179992
Autor:
Nicholas J. Martin, Julia A. Metcalf, Peifang Sun, John H. Beigel, Daniel Ewing, Robin L. Dewar, Brian J. Morrison, Kanakatte Raviprakash, Thomas C. Luke, Tauseef Rehman
Publikováno v:
BMC Health Services Research, Vol 18, Iss 1, Pp 1-11 (2018)
BMC Health Services Research
BMC Health Services Research
Background The hemagglutination-inhibition (HAI) assay is a critical component for measurement of immunogenicity in influenza vaccine development. It is unknown if the results can be influenced by sample type and anticoagulants. The purpose of this s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a258b80500cb824edb7a2f505d8f7633
http://link.springer.com/article/10.1186/s12913-018-3465-3
http://link.springer.com/article/10.1186/s12913-018-3465-3
Autor:
Bronwyn M. Gunn, Jay W. Hooper, Thomas C. Luke, Peter B. Jahrling, Dawn M. Gerhardt, Gale Smith, Theron Hamilton, Dan R. Ragland, Laura Bollinger, John M. Dye, Surender Khurana, Marisa St. Claire, Elena Postnikova, Kenneth G. Frey, Russell Byrum, Tracey Burdette, Anna N. Honko, Eddie Sullivan, Gregory M. Glenn, Subhamoy Pal, Nicholas Oberlander, Galit Alter, Steven Mazur, Krisztina Janosko, Gene G. Olinger, Hua Wu, Richard S. Bennett, Jiro Wada, Lisa E. Hensley, Jin-an Jiao, Kimberly A. Bishop-Lilly
Publikováno v:
The Journal of Infectious Diseases
Transchromosomic bovines (Tc-bovines) adaptively produce fully human polyclonal immunoglobulin (Ig)G antibodies after exposure to immunogenic antigen(s). The National Interagency Confederation for Biological Research and collaborators rapidly produce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cb1c9eb1efc23c9263d9667574f49e0
Autor:
Eddie Sullivan, John H. Beigel, Jocelyn Voell, Richard T. Davey, Kanakatte Raviprakash, Parag Kumar, Jin An Jiao, Hua Wu, Thomas C. Luke
Publikováno v:
The Lancet Infectious Diseases
Summary Background Middle East respiratory syndrome (MERS) is a severe respiratory illness with an overall mortality of 35%. There is no licensed or proven treatment. Passive immunotherapy approaches are being developed to prevent and treat several h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d9dae82917b5be82b0fae625a0c2b41
https://doi.org/10.1016/s1473-3099(18)30002-1
https://doi.org/10.1016/s1473-3099(18)30002-1